{
  "columnHierarchy": {
    "epochs": [
      {
        "id": "epoch_1",
        "name": "Run-In and Blinded Treatment",
        "instanceType": "StudyEpoch",
        "type": {
          "id": "7c79c8a0-abcf-4b44-b574-97c007615a2a",
          "code": "C98780",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Treatment Epoch",
          "instanceType": "Code"
        }
      }
    ],
    "encounters": [
      {
        "id": "enc_1",
        "name": "Day -28 Screening (Visit 1)",
        "instanceType": "Encounter",
        "type": {
          "id": "6f613cf8-a717-4d39-b96f-4461b9158b2f",
          "code": "C48262",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Screening",
          "instanceType": "Code"
        },
        "epochId": "epoch_1"
      },
      {
        "id": "enc_2",
        "name": "Day 1 Week 0 Baseline (Visit 2)",
        "instanceType": "Encounter",
        "type": {
          "id": "00bc7e32-5f06-4bab-8fb3-ced0ea6e8e9e",
          "code": "C82517",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Baseline",
          "instanceType": "Code"
        },
        "epochId": "epoch_1"
      },
      {
        "id": "enc_3",
        "name": "Day 8 Week 1 Call (Visit 3)",
        "instanceType": "Encounter",
        "type": {
          "id": "ca4e4259-d66b-4ce8-b573-f6fae4e107fd",
          "code": "C99156",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Scheduled Visit",
          "instanceType": "Code"
        },
        "epochId": "epoch_1"
      },
      {
        "id": "enc_4",
        "name": "Day 15 Week 2 (Visit 4)",
        "instanceType": "Encounter",
        "type": {
          "id": "8d6ba4ca-86ef-4a5e-8f3f-2d38168c1e08",
          "code": "C82517",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Baseline",
          "instanceType": "Code"
        },
        "epochId": "epoch_1"
      },
      {
        "id": "enc_5",
        "name": "Day 29 Week 4 (Visit 5)",
        "instanceType": "Encounter",
        "type": {
          "id": "ea77fd11-594f-41fe-a218-e599c398fc4f",
          "code": "C99156",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Scheduled Visit",
          "instanceType": "Code"
        },
        "epochId": "epoch_1"
      },
      {
        "id": "enc_6",
        "name": "Day 43 Week 6 Call (Visit 6)",
        "instanceType": "Encounter",
        "type": {
          "id": "84ef8ed6-0e45-4a9f-b9b9-2d123ceef800",
          "code": "C99156",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Scheduled Visit",
          "instanceType": "Code"
        },
        "epochId": "epoch_1"
      },
      {
        "id": "enc_7",
        "name": "Day 57 Week 8 (Visit 7)",
        "instanceType": "Encounter",
        "type": {
          "id": "73310cd9-501f-49d3-9774-61548c90fdd0",
          "code": "C99156",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Scheduled Visit",
          "instanceType": "Code"
        },
        "epochId": "epoch_1"
      },
      {
        "id": "enc_8",
        "name": "Day 85 Week 12 Randomize Responders (Visit 8)",
        "instanceType": "Encounter",
        "type": {
          "id": "a3510b2e-51fa-4a14-a601-6a7dabfdf940",
          "code": "C99156",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Scheduled Visit",
          "instanceType": "Code"
        },
        "epochId": "epoch_1"
      },
      {
        "id": "enc_9",
        "name": "Day 113 Week 16 (Visit 9)",
        "instanceType": "Encounter",
        "type": {
          "id": "3209be1f-eed3-45fc-8f24-3ed30476beb7",
          "code": "C82517",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Baseline",
          "instanceType": "Code"
        },
        "epochId": "epoch_1"
      },
      {
        "id": "enc_10",
        "name": "Day 197 Week 28 (Visit 10)",
        "instanceType": "Encounter",
        "type": {
          "id": "ee8c51cd-6da1-458a-b03d-004623510005",
          "code": "C82517",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Baseline",
          "instanceType": "Code"
        },
        "epochId": "epoch_1"
      },
      {
        "id": "enc_11",
        "name": "Day 281 Week 40 (Visit 11)",
        "instanceType": "Encounter",
        "type": {
          "id": "e4f9fe3f-99d3-433d-bd35-8548d989d46a",
          "code": "C99156",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Scheduled Visit",
          "instanceType": "Code"
        },
        "epochId": "epoch_1"
      },
      {
        "id": "enc_12",
        "name": "Day 365 Week 52 EOT/ET (Visit 12)",
        "instanceType": "Encounter",
        "type": {
          "id": "e2651674-9b53-4c58-92d3-2ce57c03d628",
          "code": "C99156",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Scheduled Visit",
          "instanceType": "Code"
        },
        "epochId": "epoch_1"
      },
      {
        "id": "enc_13",
        "name": "EOS Follow-up Week 56 (Visit 13)",
        "instanceType": "Encounter",
        "type": {
          "id": "cab8821f-ff83-45ea-a81f-8a49f1e91031",
          "code": "C99158",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Follow-up",
          "instanceType": "Code"
        },
        "epochId": "epoch_1"
      }
    ],
    "plannedTimepoints": [
      {
        "id": "pt_1",
        "visit": "Day -28",
        "epoch": "",
        "epochId": "",
        "day": "",
        "window": null,
        "encounterId": "enc_1",
        "instanceType": "Timing"
      },
      {
        "id": "pt_2",
        "visit": "Day 1",
        "epoch": "",
        "epochId": "",
        "day": "",
        "window": null,
        "encounterId": "enc_2",
        "instanceType": "Timing"
      },
      {
        "id": "pt_3",
        "visit": "Day 8",
        "epoch": "",
        "epochId": "",
        "day": "",
        "window": null,
        "encounterId": "enc_3",
        "instanceType": "Timing"
      },
      {
        "id": "pt_4",
        "visit": "Day 15",
        "epoch": "",
        "epochId": "",
        "day": "",
        "window": null,
        "encounterId": "enc_4",
        "instanceType": "Timing"
      },
      {
        "id": "pt_5",
        "visit": "Day 29",
        "epoch": "",
        "epochId": "",
        "day": "",
        "window": null,
        "encounterId": "enc_5",
        "instanceType": "Timing"
      },
      {
        "id": "pt_6",
        "visit": "Day 43",
        "epoch": "",
        "epochId": "",
        "day": "",
        "window": null,
        "encounterId": "enc_6",
        "instanceType": "Timing"
      },
      {
        "id": "pt_7",
        "visit": "Day 57",
        "epoch": "",
        "epochId": "",
        "day": "",
        "window": null,
        "encounterId": "enc_7",
        "instanceType": "Timing"
      },
      {
        "id": "pt_8",
        "visit": "Day 85",
        "epoch": "",
        "epochId": "",
        "day": "",
        "window": null,
        "encounterId": "enc_8",
        "instanceType": "Timing"
      },
      {
        "id": "pt_9",
        "visit": "Day 113",
        "epoch": "",
        "epochId": "",
        "day": "",
        "window": null,
        "encounterId": "enc_9",
        "instanceType": "Timing"
      },
      {
        "id": "pt_10",
        "visit": "Day 197",
        "epoch": "",
        "epochId": "",
        "day": "",
        "window": null,
        "encounterId": "enc_10",
        "instanceType": "Timing"
      },
      {
        "id": "pt_11",
        "visit": "Day 281",
        "epoch": "",
        "epochId": "",
        "day": "",
        "window": null,
        "encounterId": "enc_11",
        "instanceType": "Timing"
      },
      {
        "id": "pt_12",
        "visit": "Day 365",
        "epoch": "",
        "epochId": "",
        "day": "",
        "window": null,
        "encounterId": "enc_12",
        "instanceType": "Timing"
      },
      {
        "id": "pt_13",
        "visit": "Week 56",
        "epoch": "",
        "epochId": "",
        "day": "",
        "window": null,
        "encounterId": "enc_13",
        "instanceType": "Timing"
      }
    ]
  },
  "rowGroups": [
    {
      "id": "grp_1",
      "name": "Enrollment Procedure",
      "description": null,
      "childIds": [],
      "instanceType": "Activity",
      "activityNames": [
        "Informed consent",
        "Register subject using IRT system",
        "Inclusion/Exclusion Criteria",
        "C-SSRS",
        "SBQ-R",
        "PHQ-8",
        "Demographics, Medical History, Tobacco and Alcohol History, Atopic Dermatitis Disease History",
        "Review Prior/Concomitant Medications & Treatments",
        "Dispense e-Diary and instruct subjects on use",
        "Provide Patient Emergency Contact Card"
      ]
    },
    {
      "id": "grp_2",
      "name": "Medical Procedures",
      "description": null,
      "childIds": [],
      "instanceType": "Activity",
      "activityNames": [
        "Complete Physical Exam",
        "Targeted Physical Exam",
        "Vital Signs",
        "Weight/Height",
        "ECG (12-lead)"
      ]
    },
    {
      "id": "grp_3",
      "name": "Laboratory Assessments",
      "description": null,
      "childIds": [],
      "instanceType": "Activity",
      "activityNames": [
        "Hematology",
        "Coagulation Panel",
        "Serum chemistry",
        "Urinalysis",
        "Lipid Panel",
        "Serum FSH (post-menopausal) or Pregnancy Test",
        "Urine Pregnancy Test (conducted at study site)",
        "HIV Testing",
        "Hepatitis B Surface Antigen (HBsAg), Hepatitis B Surface Antibody (HBsAb), Hepatitis B Core Antibody (HBcAb), Hepatitis C Antibody (HCV Ab), Hepatitis C Viral RNA (HCV RNA)",
        "HBV DNA testing for China and Taiwan",
        "Varicella Zoster Virus (VZV IgG Ab) (adolescents only, if applicable)",
        "Tuberculosis Test",
        "Chest X-ray"
      ]
    },
    {
      "id": "grp_4",
      "name": "Pharmacokinetic",
      "description": null,
      "childIds": [],
      "instanceType": "Activity",
      "activityNames": [
        "Pharmacokinetic Blood Sampling (Post-dose)"
      ]
    },
    {
      "id": "grp_5",
      "name": "Trial Treatment",
      "description": null,
      "childIds": [],
      "instanceType": "Activity",
      "activityNames": [
        "Randomization",
        "Drug Dispensing",
        "Investigational Product Accountability",
        "Investigational Treatment Administration",
        "Review eDiary to assess completion",
        "Assess eligibility for B7451015"
      ]
    },
    {
      "id": "grp_6",
      "name": "Clinical Assessments",
      "description": null,
      "childIds": [],
      "instanceType": "Activity",
      "activityNames": [
        "Fitzpatrick Skin Type Assessment",
        "Investigator\u2019s Global Assessment (IGA)",
        "SCORing Atopic Dermatitis (SCORAD)",
        "Eczema Area and Severity Index (EASI)",
        "Total Body Surface Area (BSA from EASI)"
      ]
    },
    {
      "id": "grp_7",
      "name": "Patient-reported Outcome",
      "description": null,
      "childIds": [],
      "instanceType": "Activity",
      "activityNames": [
        "Pruritus Numerical Rating Scale -eDiary (NRS)",
        "Patient Global Assessment (PtGA)",
        "Dermatology Life Quality Index (DLQI or CDLQI)",
        "Patient-Oriented Eczema Measure (POEM)",
        "Hospital Anxiety and Depression Scale (HADS)",
        "Pruritus and Symptoms Assessment for Atopic Dermatitis - eDiary (PSAAD)",
        "EQ-5D-5L (adults) or EQ-5D-Y (ages 12-17 years)",
        "SF-36v2, Acute (adults)",
        "FACIT-F (adults) or Peds-FACIT-F (ages 12-17 years)",
        "Asthma Control Questionnaire (ACQ) for all subjects with a prior diagnosis of asthma"
      ]
    },
    {
      "id": "grp_8",
      "name": "Safety",
      "description": null,
      "childIds": [],
      "instanceType": "Activity",
      "activityNames": [
        "Serious and non-serious adverse event monitoring",
        "Assess for presence of flare",
        "Contraception Check",
        "Serum Sample for Baseline Viral Screen"
      ]
    }
  ],
  "footnotes": [
    "a. Complete physical examinations must be performed by the investigator, sub investigator or a qualified health professional per local guidelines.",
    "b. Vital Signs include sitting blood pressure, pulse, respiratory rate, and temperature measured after at least 5 minutes of rest.",
    "c. Hematology includes: Hemoglobin, hematocrit, red blood cells, white blood cells, neutrophils (%, absolute), lymphocytes (%, absolute), monocytes (%, absolute), eosinophils (%, absolute), basophils (%, absolute), platelets, reticulocyte count, RBC Indices (MCH, MCHC, MCV, RBC Morphology), lymphocyte subsets and markers (Total T cells [CD3+], CD4+ T cells [CD3+CD4+], CD8+ T cells [CD3+CD8+], NK cells [CD3-CD16+CD56+], B cells [CD3-CD19 +).",
    "d. Coagulation panel includes: Activated Partial Thromboplastin Time (APTT), Prothrombin Time/International Normalized Ratio (PT/INR).",
    "e. Serum chemistry includes: blood urea nitrogen (BUN), serum creatinine, creatine phosphokinase, glucose, Ca++, Na+, K+, Cl-, total CO2, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), total, indirect and direct bilirubin, alkaline phosphatase, lactate dehydrogenase, uric acid, albumin and total protein.",
    "f. Urinalysis includes: pH, Glucose (qualitative), Protein (qualitative), Blood (qualitative), Ketones, Nitrites, Leukocyte esterase, Microscopy and/or culture (performed as appropriate).",
    "h. Lipid Panel includes: total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides. A minimum of 8-hour fasting is required for lipid profile evaluation at the following Rescue Visits: Day 1, Week 4, Week 12 and EOS visits.",
    "i. Urine pregnancy test must be performed at every site visit prior to dosing with the investigational product for female subjects of childbearing potential including adolescents aged 12 years and older regardless of whether they have experienced menarche.",
    "j. Subjects should take the medication from study Days 1 to 85 of the rescue treatment. Subjects will be encouraged to take the medication in the morning whenever possible; however, at study visit days, subjects are to be instructed to refrain from dosing at home and are to take the dose in the clinic.",
    "k. Subjects who complete EOT will be assessed for eligibility for participation in long-term extension study B7451015 as noted in Section 6.5.7.",
    "l. Pruritus Numerical Rating Scale (NRS) will be assessed using an eDiary, and will be collected daily in the eDiary from Study Days 1-15 during the rescue treatment and then only on study visit days at the investigative site thereafter. PSAAD will be completed daily (in selected countries) in the eDiary from Day 1 through the End of Study (EOS) visit during rescue treatment. At every visit, the study coordinator will review the eDiary for completeness and counsel the subject on how to complete the items in the daily eDiary, if needed.",
    "m. DLQI will be completed by adult subjects only. Adolescents 12-17 years of age will complete the CDLQI instead.",
    "n. The EuroQol Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) will be completed by adult subjects only. Adolescents 12-17 years of age will complete the EuroQol Quality of Life 5-Dimension, Youth Scale (EQ-5D-Y) in select countries.",
    "o. SF-36v2 will be completed by adult subjects only. Adolescents 12-17 years of age will not complete this assessment.",
    "p. FACIT-F will be completed by adult subjects only. Adolescents 12-17 years of age will complete the Peds-FACIT-F instead.",
    "q. Collect weight for all subjects and height for adolescents only (12 to <18 years old).",
    "r. Following one year of total exposure to study drug since the last TB test, all subjects in regions which are above a low-risk for Tuberculosis (ie, >10/100,000 prevalence) will undergo tuberculosis (TB) testing. A chest X-ray will be performed to aid in TB status determination for all adults, and recommended for adolescents according to local guidelines and standard of care in countries with a high incidence rate of TB.",
    "s. In China and Taiwan only: For subjects who had HBV DNA testing at Screening, HBV DNA testing is repeated at Rescue Week 12 or at an early termination visit. A single positive HBV DNA test result above the LLQ for a subject requires immediate and permanent discontinuation from treatment. Refer to Section 7.6.2.1.",
    "t. Post-screening, if there are \u201cyes\u201d answers on items 4, 5 or on any behavioral question of the Since Last Visit C-SSRS a risk assessment by a qualified mental health professional (MHP) should be done to determine whether it is safe for the subject to continue to participate in the trial.",
    "g. Vital Si g ns i ncl u de sitti n g bl o o d press ure, p ulse, res pirat or y rate, a n d te m perat ure meas ure d after at least 5 mi n utes of rest.",
    "u. A P K bl o o d sa m ple will be c ollecte d at 2. 0 h o urs ( \uf0b13 0 mi n) p ost d ose of o pe n -la bel st u d y dr u g ( 2 0 0 m g) at t he Wee k 1 2 visit. F or Earl y Ter mi nati o n ( E T) visits, if t he s u bject disc o nti n u es bef ore Wee k 4 , d o n ot c ollect a P K sa m ple. If t he E T visit occ urs at or after Wee k 4 a n d bef ore Wee k 1 2, c ollect a P K sa m ple o nl y if t he s u bject ta kes t he i n vesti gati o nal pr o d uct at t he site visit. C CI --- Page 30 --- P F- 0 4 9 6 5 8 4 2 B 7 4 5 1 0 1 4 Fi nal P r otoc ol A me n d me nt 5, 2 8 Oct o ber 2 0 1 9 P FI Z E R C O N FI D E N TI A L Pa ge 3 0",
    "v. S u bjects s h o ul d ta ke t he me dicati o n fr o m st u d y Da ys 1 t o 3 6 5. S u bjects will be e nc o ura ge d t o ta ke t he me dicati o n i n t he m or ni n g w he ne ver p ossi ble; h o we ver, at st u d y visit da ys, s u bjects are t o be i nstr ucte d t o refrai n fr o m d osi n g at h o me a n d are t o ta ke t he d ose i n t he cl i nic. I nstr uct s u bjects re gar di n g pr o per st ora ge c o n diti o ns f or i n vesti gati o nal pr o d uct o n Da y 1.",
    "w. S u bjects w h o are n o n res p o n ders b ut c o m plete t he 1 2 wee k r u n- i n treat me nt a n d s u bjects w h o are re p o n ders at E O T will be assesse d f or eli gi bilit y f or partici pati o n i n l o n g -ter m e xte nsi o n st u d y B7 4 5 1 0 1 5 as n ote d i n Secti o n 6. 3. 5 .",
    "x. Pr urit us N u merical Rati n g Scale ( N R S) will be assesse d usi n g a n e Diar y dail y d uri n g t he scree ni n g peri o d a n d fr o m St u d y Da y 1 t o 1 5. After Da y 1 5, t he Pr uri t us N R S will be c o mplete d o nl y o n st u d y visit da ys i n t he e Diar y. At t he Scree ni n g v isit, site staff will dis pe nse t he electr o nic ta blet (e P R O de vice ) a n d re vie w i nstr ucti o ns f or c o m pleti o n of t he s u bject e Diar y f or t he N R S. At e ver y visit, t he st u d y c o or di nat or will revie w t he e Diar y f or c o m plete ness a n d c o u nsel t he s u bject o n h o w t o co m p lete t he ite ms i n t he dail y e Diar y, if nee de d.",
    "y. D L QI will be c o m plete d b y a d ult s u bjects o nl y. A d olesce nts 1 2 -1 7 years of a ge will c o m plete t he C D L QI i nstea d.",
    "1. I N T R O D U C TI O N",
    "2. S T U D Y O B J E C TI V E S A N D E N D P OI N T S St u d y o bjecti ves a n d c orres p o n di n g e n d p oi nts are pr o vi de d i n Ta ble 1. T a ble 1. O bjecti ves a n d E n d p oi nts Pri m ar y O bjecti ve: Pri m ar y E n d p oi nt: \uf0b7 T o e val uate a n d c o m pare t he mai nte na nce of effect of t wo d oses of P F -0 4 9 6 5 8 4 2 ( 2 0 0 m g a n d 1 0 0 m g o nce dail y ( Q D)) a n d place b o i n s u bjects a ge d 1 2 a n d a b o ve wit h m o derate t o se vere at o pic der matitis w h o res p o n d t o i nitial o pe n-la bel r u n-i n treat me nt of 2 0 0 m g P F -0 4 9 6 5 8 4 2 Q D.",
    "3. Res p o nse bas ed o n ac hie vi n g \u22654 p oi nt i m pr o ve me nt i n t he se verit y of pr urit us N u merical Rati n g Scale ( N R S) fr o m baseli ne at all sc he d ule d ti me p oi nts.",
    "4. Perce nt c ha n ge fr o m baseli ne i n perce nt B o d y S urface Area ( B S A) at all sc he d ule d ti me p oi nts.",
    "5. Perce nt c ha n ge fr o m baseli ne i n S C O Ri n g At o pic Der matitis ( S C O R A D) s u bjecti ve assess me nts of itc h a n d slee p l oss at all sc he d ule d ti me p oi nts.",
    "6. Res p o nse base d o n ac hie vi n g a \uf0b35 0 % a n d \uf0b37 5 % i mpr o ve me nt i n S C O R A D ( S C O R A D -5 0, S C O R A D -7 5) fr o m baseli ne a t all sc he d ule d ti me p oi nts. Cli n ic al Effic ac y Assess me nts i n S u bjects Re q uiri n g Resc ue Tre at m e nt:"
  ]
}